Asciminib, a first-in-class STAMP inhibitor, provides durable molecular response in patients (pts) with chronic myeloid leukemia (CML) harboring the T315I mutation: Primary efficacy and safety results from a phase 1 trial Meeting Abstract
| Authors: | Cortes, J. E.; Hughes, T. P.; Mauro, M. J.; Hochhaus, A.; Rea, D.; Goh, Y. T.; Janssen, J.; Steegmann, J. L.; Heinrich, M. C.; Talpaz, M.; Etienne, G.; Breccia, M.; Deininger, M. W.; le Coutre, P. D.; Lang, F.; Aimone, P.; Polydoros, F.; Cacciatore, S.; Stenson, L.; Kim, D. W. |
| Abstract Title: | Asciminib, a first-in-class STAMP inhibitor, provides durable molecular response in patients (pts) with chronic myeloid leukemia (CML) harboring the T315I mutation: Primary efficacy and safety results from a phase 1 trial |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607547200141 |
| DOI: | 10.1182/blood-2020-139677 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 47 -- Source: Wos |
